Latest Conference Articles

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.

At ARVO 2024, Roger Goldberg, MD explores the greater reductions in hard exudates achieved with faricimab than aflibercept in eyes with DME.

In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.

In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.

At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.

In an interview with HCPLive, Karlin and Robinson discuss the phase 2b trial on MM120 for generalized anxiety disorder.

Daniel Su, MD describes the promise of APX3330 for delaying or preventing diabetic retinopathy progression in a post-hoc analysis of the ZETA-1 trial.

At APA 2024, HCPLive interviewed APA members about how DSM-5-TR classifies psychiatric disorders differently than previous iterations.

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

Nelson discusses how personality disorder care has been slow to apply evidence into practice—and how it's affecting patients.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

The utility of second-generation antipsychotics and clozapine has been less advantageous than it could be, Kane explained.

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

McIntyre explains why GLP-1/GIP receptor agonists like semaglutide may alter cognitive and psychiatric care similar to cardiometabolic disease.

Devanand reviews lecanemab and the advent of blood biomarkers for dementia and Alzheimer's management at APA 2024.

Kane explains why newer long-acting injectables and clozapine may be under-utilized still in the management of schizophrenia.

Despite often presenting to the hospital with similar non-psychiatric conditions, patients with schizophrenia often experience a more difficult care process than those without.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

Four-year, phase 3 data from APA 2024 show olanzapine/samidorphan provided consistent antipsychotic efficacy and weight-related safety in patients with either schizophrenia or bipolar I disorder.

During this discussion, Ohuabunwa discussed additional takeaways from her ACP conference talk on postdischarge care and other tips for internal medicine physicians.

This discussion with Ohuabunwa was held at the ACP conference and covered inpatient geriatrics assessment tips for internal medicine physicians.

Matthew Nudy, MD, discusses a trio of meta-analyses examining the effects of intensive blood pressure control on various targets.

Chun spoke in this interview segment about more recommendations for internal medicine physicians to give older adults related to aging, dementia, and statin use.

Solomon discusses the health care system’s role in mitigating climate change and how health care professionals can help protect and inform their patients.

In this interview, Chun discussed recommendations for internal medicine physicians to give older adults for slowing aging as well as evidence for statins.